| 2024/10/04 22:00:02 | |
|---|---|
| Price | |
| 28.58 USD | |
| Difference | 0.85% (0.24) |
General attributes
| ISIN | US7170811035 |
| Symbol | PFE |
| Exchange | NYSE |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 0 |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 28.61 USD (100) |
| Ask (Ask size) | 28.66 USD (100) |
| Open | 28.29 USD |
| High | 28.59 USD |
| Low | 28.24 USD |
| Close (prev. day) | 28.34 USD |
| VWAP | 28.490514 USD |
| Volume (pcs) | 28,786,884 |
| Trading volume | 820,256,768.06 |
| Number of trades | 146,059 |
| Last size | - |
Futures and Options
| Related Futures | 15 |
| Related Options | - |
PDF Downloads
| Company report: PFIZER INC |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/09/27 |
|
Global Equity Ratings |
|
| 2024/09/11 |
|
Global Equity Ratings |
|
| 2024/09/05 |
|
Global Equity Ratings |
|
| 2024/08/12 |
|
Global Equity Ratings |
|
| 2024/07/24 |
|
Global Equity Ratings |
|
| 2024/10/04 22:00:02 | |
|---|---|
| Price | |
| 28.58 USD | |
| Difference | 0.85% (0.24) |
General attributes
| ISIN | US7170811035 |
| Symbol | PFE |
| Exchange | NYSE |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 0 |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 28.61 USD (100) |
| Ask (Ask size) | 28.66 USD (100) |
| Open | 28.29 USD |
| High | 28.59 USD |
| Low | 28.24 USD |
| Close (prev. day) | 28.34 USD |
| VWAP | 28.490514 USD |
| Volume (pcs) | 28,786,884 |
| Trading volume | 820,256,768.06 |
| Number of trades | 146,059 |
| Last size | - |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +5.71% | -17.98% | -28.77% |
| Perf (abs.) | +1.41 | -5.70 | -10.50 |
| Beta | 0.23 | 0.26 | 0.39 |
| Volatility | 22.91 | 25.17 | 26.32 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 28.63 USD (27,525,851) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 29.06 USD (28,041,143) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 28.87 USD (31,891,358) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 28.58 USD (38,003,649) |
| YTD High | date | 31.54 USD (2024/07/30) |
| YTD Low | date | 25.20 USD (2024/04/26) |
| 52 Weeks High | date | 33.92 USD (2023/10/16) |
| 52 Weeks Low | date | 25.20 USD (2024/04/26) |
All listings for PFIZER INC
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/10/04 | 17:36 | 25.91 EUR | 0.80 | 270 |
| Vienna Stock Exchange | 2024/10/04 | 17:32 | 25.895 EUR | 0.00 | 6 |
| Tradegate | 2024/10/04 | 22:26 | 26.035 EUR | 1.29 | 259 |
| Stuttgart | 2024/10/04 | 20:33 | 25.955 EUR | 0.14 | 24 |
| NYSE | 2024/10/04 | 22:00 | 28.58 USD | 820.26 | 146,059 |
| Munich | 2024/10/04 | 17:27 | 25.855 EUR | 0.02 | 3 |
| London Stock Exchange | 2024/10/04 | 17:35 | 28.35 USD | 0.00 | 20 |
| Hanover | 2024/10/04 | 17:25 | 25.87 EUR | 0.00 | 4 |
| Hamburg | 2024/10/04 | 17:25 | 25.87 EUR | 0.01 | 4 |
| Frankfurt | 2024/10/04 | 21:51 | 25.98 EUR | 0.13 | 19 |
| Euronext Milan MTF Trading After Hours | 2024/10/03 | 18:10 | 25.815 EUR | 0.01 | 2 |
| Euronext Milan MTF Global Equity Market | 2024/10/04 | 17:44 | 25.885 EUR | 0.25 | 12 |
| Duesseldorf | 2024/10/04 | 19:30 | 26.02 EUR | 0.00 | 6 |
| Berlin | 2024/10/04 | 08:08 | 25.705 EUR | 0.00 | 2 |
Company Logo
Contact Details
| - |
| - - |
| - - - - |
| Telefon: - |
| Fax: - |
| E-mail: - |
PDF Downloads
| Company report: PFIZER INC | |
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY. |
Members of Management Board
| Dan Littman | Member of Board of Directors |
| Helen Hobbs | Member of Board of Directors |
| Scott Gottlieb | Member of Board of Directors |
| Susan Desmond-Hellmann | Member of Board of Directors |
| Susan Hockfield | Member of Board of Directors |
| Cyrus Taraporevala | Member of Board of Directors |
| James Quincey | Member of Board of Directors |
| James Smith | Member of Board of Directors |
| Joseph Echevarria | Member of Board of Directors |
| Ronald Blaylock | Member of Board of Directors |
| Shantanu Narayen | Member of Board of Directors |
| Suzanne Johnson | Member of Board of Directors |
| Albert Bourla | Chairman of Managing Board |
| Aamir Malik | Member of Executive Committee |
| Alexandre de Germay | Member of Executive Committee |
| Chris Boshoff | Member of Executive Committee |
| Dave Denton | Member of Executive Committee |
| Douglas M. Lankler | Member of Executive Committee |
| Lidia Fonseca | Member of Executive Committee |
| Mikael Dolsten | Member of Executive Committee |
| Mike McDermott | Member of Executive Committee |
| Payal Sahni Becher | Member of Executive Committee |
| Rady A. Johnson | Member of Executive Committee |
| Sally Susman | Member of Executive Committee |